Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

PFE US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Pfizer Inc(PFE US)

$28.72-0.120.40%(Market Open · 16:38:23 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

PFE US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Pfizer Inc(PFE US)

$28.72-0.120.40%(Market Open · 16:38:23 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Pfizer Inc — Company Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Albert Bourla
Headquarters
New York City, NY, US
IPO Date
Jun 1, 1972
Employees
75,000
Website
www.pfizer.com

Key Metrics

Price
$27.80
Market Cap
$158.44B
Revenue (TTM)
$14.45B
Net Income (TTM)
$2.69B
EPS (TTM)
0.47
P/E (TTM)
21.15
P/B (TTM)
1.76
Dividend Yield
6.70%
ROE (TTM)
2.98%
ROA (TTM)
1.29%
Operating Margin
27.90%

Pfizer Inc — Company Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Albert Bourla
Headquarters
New York City, NY, US
IPO Date
Jun 1, 1972
Employees
75,000
Website
www.pfizer.com

Key Metrics

Price
$27.80
Market Cap
$158.44B
Revenue (TTM)
$14.45B
Net Income (TTM)
$2.69B
EPS (TTM)
0.47
P/E (TTM)
21.15
P/B (TTM)
1.76
Dividend Yield
6.70%
ROE (TTM)
2.98%
ROA (TTM)
1.29%
Operating Margin
27.90%
Beta
0.23

Dividends

Last Dividend
$0.43
Last Yield
0.07%

Summary

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Website
www.pfizer.com
Location
New York City, NY, US
Phone212 733 2323
Employees75,000
CEOAlbert Bourla
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJun 1, 1972

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(6.6K)

Expand
  • 13F-HRQuarterly report (institutional investment manager holdings)12 Nov
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers3 Nov
  • Form 4BOURLA ALBERT3 Nov
  • 10-QQ3ended 27 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • Form 4BOURLA ALBERT16 Oct
  • SC 13GTRex Bio, Inc.16 Oct
  • Form 4BOURLA ALBERT14 Oct
  • Form 4BOURLA ALBERT1 Oct
  • Form 4Buckley Mortimer J29 Sep
  • Form 4Echevarria Joseph29 Sep
  • Form 4NARAYEN SHANTANU29 Sep
  • Form 4Quincey James29 Sep
  • Form 4Taraporevala Cyrus29 Sep
  • Form 4SMITH JAMES C29 Sep
  • Form 4BOURLA ALBERT16 Sep
  • Form 4BOURLA ALBERT1 Sep
  • N-PXAnnual report of proxy voting record31 Aug
  • Form 3Guegan Cecile28 Aug
  • Form 4BOURLA ALBERT17 Aug

News

  • Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?10:31AM
  • A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer09:17AM
  • 2 Bargain Stocks to Buy With $1,000 in November07:11AM
  • Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug12 Nov
  • Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program12 Nov
  • Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy12 Nov
  • Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug12 Nov
  • Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development11 Nov
  • Pfizer secures up to $1.5 billion from Blackstone for obesity drug development11 Nov
  • Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program11 Nov
  • Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year11 Nov
  • 3 Magnificent Dividend Stocks Yielding 4% or More to Buy in November10 Nov
  • Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference10 Nov
  • Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock10 Nov
  • Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know9 Nov
  • Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 20289 Nov
  • Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials7 Nov
  • 3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market6 Nov
  • Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher6 Nov
  • November Buy: 6 IDEAL S&P 500 'Safer' Dividend Dogs6 Nov

Mentions in Filings

  • competitors include argenx SE, AstraZeneca plc, <strong>Pfizer</strong>, Inc., and Priovant Therapeutics, Inc. We also face competition from academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testi …
    Jade Biosciences, Inc.Pfizer Inc·10-Q - Quarterly report Q3·Q3 26·07:29AM
  • … e also served as chairman and as a member of the company’s audit and compensation committees. Mr. Tarnok has extensive pharmaceutical industry experience in a wide range of functional areas. He spent most of his career at <strong>Pfizer</strong> Inc., which he joined in 1989 as Finance Director-US and Puerto Rico Manufacturing and later served as a Senior Vice President in its US Pharmaceutical Division. Mr. Tarnok holds a Bachelor of Science in Accounting from S …
    Ionetix Corp / DE /Pfizer Inc·424B3 - PROSPECTUS·Q4 26·07:18AM
  • … April 1989 Bain & Company Japan Joined N. Incorporated February 1992, Amersham Pharmacia Biotech Co., Ltd. (Currently Global Life Sciences Technology) Joined Nology Japan Co., Ltd. November 1998: Monsanto Japan Ltd. (now <strong>Pfizer</strong> Inc.) Joining the company Joined Advantage Partners Co., Ltd. in November 1999. September 2003, Representative of Life Science Management Co., Ltd. Director and Partner March 2004, Fast Track Initiative Co., Ltd. Director …
    KNC Laboratories Co., Ltd.Pfizer Inc·Interim Report - Semi-Annual Report (2026.04.01-2027.03.31)·13 Nov·01:31AM
  • are aware of several companies that are developing ADCs, bispecific antibodies and cancer immunotherapies, including companies developing ADCs directed to the same targets as STRO-004, STRO-006 and STRO-227. For example, <strong>Pfizer</strong> has an approved ADC targeting TF, TIVDAK®, and is developing sigvotatug vedotin, PF-08046876, and PF-08052667, three ADCs targeting ITGB6. In addition, large pharmaceutical companies and smaller biotechnology companies ar …
    SUTRO BIOPHARMA, INC.Pfizer Inc·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … eutical company, and was responsible for operational and legal oversight. Prior to Phenomix, Mr. Aker was Senior Corporate Counsel at SUGEN, Inc. (“SUGEN”), a wholly-owned subsidiary of Pharmacia, until its acquisition by <strong>Pfizer</strong> Inc. Prior to SUGEN, Mr. Aker was in private practice with various law firms. Mr. Aker received his B.A. in International Relations from the University of California, Davis and his J.D. from Santa Clara University. Cris …
    Werewolf Therapeutics, Inc.Pfizer Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • et for the manufacture and supply of APIs and intermediates is large with many established companies. These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, <strong>Pfizer</strong> Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermedia …
    CODEXIS, INC.Pfizer Inc·10-Q - Quarterly report Q3·Q3 26·12 Nov

Key Stats

Trading

Px/Chg 1D$27.80 / -1.14%
Prev Close$28.81
% of 52Wk H97.40%
Avg Volume39.04M
Beta0.23
Mkt Cap158.44B
FD Mkt Cap162.15B

Float

Shrs Out/Float5.70B / 5.69B
Short Float0.03%
Days to Cover2.69
Stock Repurchased$0.00

Current Valuation

EV221.50B
EV/EBITDA13.23
EV/Sales3.50
P/B1.76
P/S2.50
FCF Yield1.38%
ROE2.98%
ROA1.29%
Current Ratio1.25

Dividend

Cash$0.43
Yield6.70%
Yield (TTM)6.70%

Estimates

P/E21.15
Est P/E0.00
Est EPS0.72
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings13.146.8873.4717.09-90.6958.95
Price / Sales5.282.152.632.158.5110.96
Price / Book Value1.802.261.761.521.731.76
Price / Free Cash Flow32.168.2932.6913.9433.1872.71
ENTERPRISE VALUE METRICS
Enterprise Value222,044.9250,494.8224,972.1197,228.8216,029.6221,499.4
Enterprise Value / Sales7.402.503.783.1012.3015.33
Enterprise Value / EBITDA74.086.1123.5410.88285.7544.11
Enterprise Value / EBIT-16.156.9668.8617.75-232.0457.71

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-6.3%81,288.0100,330.059,553.063,627.062,579.0
Gross Income-1.6%46,875.062,090.030,340.041,846.044,014.0
EBITDA-16.3%30,793.041,031.09,557.018,127.015,096.0
EBIT-20.6%25,602.035,967.03,267.011,114.010,191.0
Net Income-23%22,147.031,365.02,133.08,020.07,770.0
EPS (Diluted)-23.1%3.885.470.371.411.36
BALANCE SHEET
Cash & ST Inv-18.7%31,069.022,732.012,690.020,477.013,596.0
Total Assets3.5%181,477.0197,206.0226,501.0213,396.0208,160.0
Total Liabilities3.9%104,014.0101,289.0137,213.0124,899.0121,385.0
Total Shareholder Equity2.9%77,201.095,661.089,014.088,203.086,476.0
CASH FLOW
Net Operating Cash Flow-22.6%32,580.029,267.08,700.012,744.011,705.0
Cap Ex-76.5%-2,711.0-3,236.0-3,907.0-2,909.0-2,629.0
Free Cash Flow-25.8%29,869.026,031.04,793.09,835.09,076.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)28.70
Basic Shares5,699.44
Market Cap163,545.4
Diluted Shares5,751.00
Fully Diluted Shares Outstanding5,751.00
Fully Diluted Market Cap165,024.9
+Consolidated Debt62,671.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,824.0
−Short-term Investments-12,448.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest299.0
+Pension Liabilities—
Enterprise Value224,691.4

Segment data

Revenue

by Products and services

  • Biopharma Segment98%
  • Segment Reporting, Reconciling Item, Corporate Nonsegment2%

Revenue

by Geography

  • United States59%
  • Developed Rest Of World26%
  • Emerging Markets15%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US

Beta
0.23

Dividends

Last Dividend
$0.43
Last Yield
0.07%

Summary

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Website
www.pfizer.com
Location
New York City, NY, US
Phone212 733 2323
Employees75,000
CEOAlbert Bourla
Sector
Health Care
Industry
Pharmaceuticals
IPO DateJun 1, 1972

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(6.6K)

Expand
  • 13F-HRQuarterly report (institutional investment manager holdings)12 Nov
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers3 Nov
  • Form 4BOURLA ALBERT3 Nov
  • 10-QQ3ended 27 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • Form 4BOURLA ALBERT16 Oct
  • SC 13GTRex Bio, Inc.16 Oct
  • Form 4BOURLA ALBERT14 Oct
  • Form 4BOURLA ALBERT1 Oct
  • Form 4Buckley Mortimer J29 Sep
  • Form 4Echevarria Joseph29 Sep
  • Form 4NARAYEN SHANTANU29 Sep
  • Form 4Quincey James29 Sep
  • Form 4Taraporevala Cyrus29 Sep
  • Form 4SMITH JAMES C29 Sep
  • Form 4BOURLA ALBERT16 Sep
  • Form 4BOURLA ALBERT1 Sep
  • N-PXAnnual report of proxy voting record31 Aug
  • Form 3Guegan Cecile28 Aug
  • Form 4BOURLA ALBERT17 Aug

News

  • Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?10:31AM
  • A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer09:17AM
  • 2 Bargain Stocks to Buy With $1,000 in November07:11AM
  • Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug12 Nov
  • Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program12 Nov
  • Blackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy12 Nov
  • Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug12 Nov
  • Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development11 Nov
  • Pfizer secures up to $1.5 billion from Blackstone for obesity drug development11 Nov
  • Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program11 Nov
  • Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year11 Nov
  • 3 Magnificent Dividend Stocks Yielding 4% or More to Buy in November10 Nov
  • Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference10 Nov
  • Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock10 Nov
  • Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know9 Nov
  • Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 20289 Nov
  • Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials7 Nov
  • 3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market6 Nov
  • Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher6 Nov
  • November Buy: 6 IDEAL S&P 500 'Safer' Dividend Dogs6 Nov

Mentions in Filings

  • competitors include argenx SE, AstraZeneca plc, <strong>Pfizer</strong>, Inc., and Priovant Therapeutics, Inc. We also face competition from academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testi …
    Jade Biosciences, Inc.Pfizer Inc·10-Q - Quarterly report Q3·Q3 26·07:29AM
  • … e also served as chairman and as a member of the company’s audit and compensation committees. Mr. Tarnok has extensive pharmaceutical industry experience in a wide range of functional areas. He spent most of his career at <strong>Pfizer</strong> Inc., which he joined in 1989 as Finance Director-US and Puerto Rico Manufacturing and later served as a Senior Vice President in its US Pharmaceutical Division. Mr. Tarnok holds a Bachelor of Science in Accounting from S …
    Ionetix Corp / DE /Pfizer Inc·424B3 - PROSPECTUS·Q4 26·07:18AM
  • … April 1989 Bain & Company Japan Joined N. Incorporated February 1992, Amersham Pharmacia Biotech Co., Ltd. (Currently Global Life Sciences Technology) Joined Nology Japan Co., Ltd. November 1998: Monsanto Japan Ltd. (now <strong>Pfizer</strong> Inc.) Joining the company Joined Advantage Partners Co., Ltd. in November 1999. September 2003, Representative of Life Science Management Co., Ltd. Director and Partner March 2004, Fast Track Initiative Co., Ltd. Director …
    KNC Laboratories Co., Ltd.Pfizer Inc·Interim Report - Semi-Annual Report (2026.04.01-2027.03.31)·13 Nov·01:31AM
  • are aware of several companies that are developing ADCs, bispecific antibodies and cancer immunotherapies, including companies developing ADCs directed to the same targets as STRO-004, STRO-006 and STRO-227. For example, <strong>Pfizer</strong> has an approved ADC targeting TF, TIVDAK®, and is developing sigvotatug vedotin, PF-08046876, and PF-08052667, three ADCs targeting ITGB6. In addition, large pharmaceutical companies and smaller biotechnology companies ar …
    SUTRO BIOPHARMA, INC.Pfizer Inc·10-Q - Quarterly report Q3·Q3 26·12 Nov
  • … eutical company, and was responsible for operational and legal oversight. Prior to Phenomix, Mr. Aker was Senior Corporate Counsel at SUGEN, Inc. (“SUGEN”), a wholly-owned subsidiary of Pharmacia, until its acquisition by <strong>Pfizer</strong> Inc. Prior to SUGEN, Mr. Aker was in private practice with various law firms. Mr. Aker received his B.A. in International Relations from the University of California, Davis and his J.D. from Santa Clara University. Cris …
    Werewolf Therapeutics, Inc.Pfizer Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • et for the manufacture and supply of APIs and intermediates is large with many established companies. These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, <strong>Pfizer</strong> Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermedia …
    CODEXIS, INC.Pfizer Inc·10-Q - Quarterly report Q3·Q3 26·12 Nov

Key Stats

Trading

Px/Chg 1D$27.80 / -1.14%
Prev Close$28.81
% of 52Wk H97.40%
Avg Volume39.04M
Beta0.23
Mkt Cap158.44B
FD Mkt Cap162.15B

Float

Shrs Out/Float5.70B / 5.69B
Short Float0.03%
Days to Cover2.69
Stock Repurchased$0.00

Current Valuation

EV221.50B
EV/EBITDA13.23
EV/Sales3.50
P/B1.76
P/S2.50
FCF Yield1.38%
ROE2.98%
ROA1.29%
Current Ratio1.25

Dividend

Cash$0.43
Yield6.70%
Yield (TTM)6.70%

Estimates

P/E21.15
Est P/E0.00
Est EPS0.72
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings13.146.8873.4717.09-90.6958.95
Price / Sales5.282.152.632.158.5110.96
Price / Book Value1.802.261.761.521.731.76
Price / Free Cash Flow32.168.2932.6913.9433.1872.71
ENTERPRISE VALUE METRICS
Enterprise Value222,044.9250,494.8224,972.1197,228.8216,029.6221,499.4
Enterprise Value / Sales7.402.503.783.1012.3015.33
Enterprise Value / EBITDA74.086.1123.5410.88285.7544.11
Enterprise Value / EBIT-16.156.9668.8617.75-232.0457.71

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-6.3%81,288.0100,330.059,553.063,627.062,579.0
Gross Income-1.6%46,875.062,090.030,340.041,846.044,014.0
EBITDA-16.3%30,793.041,031.09,557.018,127.015,096.0
EBIT-20.6%25,602.035,967.03,267.011,114.010,191.0
Net Income-23%22,147.031,365.02,133.08,020.07,770.0
EPS (Diluted)-23.1%3.885.470.371.411.36
BALANCE SHEET
Cash & ST Inv-18.7%31,069.022,732.012,690.020,477.013,596.0
Total Assets3.5%181,477.0197,206.0226,501.0213,396.0208,160.0
Total Liabilities3.9%104,014.0101,289.0137,213.0124,899.0121,385.0
Total Shareholder Equity2.9%77,201.095,661.089,014.088,203.086,476.0
CASH FLOW
Net Operating Cash Flow-22.6%32,580.029,267.08,700.012,744.011,705.0
Cap Ex-76.5%-2,711.0-3,236.0-3,907.0-2,909.0-2,629.0
Free Cash Flow-25.8%29,869.026,031.04,793.09,835.09,076.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)28.70
Basic Shares5,699.44
Market Cap163,545.4
Diluted Shares5,751.00
Fully Diluted Shares Outstanding5,751.00
Fully Diluted Market Cap165,024.9
+Consolidated Debt62,671.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-1,824.0
−Short-term Investments-12,448.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest299.0
+Pension Liabilities—
Enterprise Value224,691.4

Segment data

Revenue

by Products and services

  • Biopharma Segment98%
  • Segment Reporting, Reconciling Item, Corporate Nonsegment2%

Revenue

by Geography

  • United States59%
  • Developed Rest Of World26%
  • Emerging Markets15%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US